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ABSTRACT
Colorectal cancer (CRC) is prevalent worldwide, and treatment often involves 
surgery and genotoxic chemotherapy. DNA repair mechanisms, such as base 
excision repair (BER) and mismatch repair (MMR), may not only influence tumour 
characteristics and prognosis but also dictate chemotherapy response. Defective 
MMR contributes to chemoresistance in colorectal cancer. Moreover, BER affects 
cellular survival by repairing genotoxic base damage in a process that itself can 
disrupt metabolism. In this study, we characterized BER and MMR gene expression 
in colorectal tumours and the association between this repair profile with patients’ 
clinical and pathological features. In addition, we exploited the possible mechanisms 
underlying the association between altered DNA repair, metabolism and response 
to chemotherapy. Seventy pairs of sporadic colorectal tumour samples and adjacent 
non-tumour mucosal specimens were assessed for BER and MMR gene and protein 
expression and their association with pathological and clinical features. MMR-deficient 
colon cancer cells (HCT116) transiently overexpressing MPG or XRCC1 were treated 
with 5-FU or TMZ and evaluated for viability and metabolic intermediate levels. 
Increase in BER gene and protein expression is associated with more aggressive 
tumour features and poor pathological outcomes in CRC. However, tumours with 
reduced MMR gene expression also displayed low MPG, OGG1 and PARP1 expression. 
Imbalancing BER by overexpression of MPG, but not XRCC1, sensitises MMR-deficient 
colon cancer cells to 5-FU and TMZ and leads to ATP depletion and lactate accumulation. 
MPG overexpression alters DNA repair and metabolism and is a potential strategy to 
overcome 5-FU chemotherapeutic resistance in MMR-deficient CRC.
INTRODUCTION
Colorectal carcinoma (CRC) is the third most 
common malignancy worldwide, and over 1 million new 
cases of colorectal carcinoma are diagnosed each year 
[1]. Disease prognosis and therapy selection for CRC 
largely depends on pathology-related staging following 
the tumour-node-metastasis (TNM) classification and 
staging system. Despite widely used, TNM staging 
seldom predicts the clinical outcome of CRC patients 
accurately. Highlighting the limitations of the TNM 
classification system is the observation that 20-40% of 
patients with relatively low-grade, stage II colorectal 
cancer rapidly worsen and die [2, 3]. Moreover, despite 
significant advances in diagnosis and treatment, CRC-
related mortality remains unchanged for the past 20 years 
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2017
Oncotarget2www.impactjournals.com/oncotarget
and patients with advanced disease derive limited if any 
benefit from the recent advances in adjuvant therapy [4].
Therapy for CRC includes surgery, radiation and/
or chemotherapeutic schemes, largely based on the use 
of 5-fluorouracil (5-FU) and its prodrug capecitabine [5]. 
Treatment with 5-FU results in thymidylate synthase (TS) 
inhibition, depletion of thymidine triphosphates (TTPs) 
available for DNA synthesis, and misincorporation of 
FdUTP (5-FdUrd triphosphate) into DNA, and/or of FUTP 
(5-fluorouridine triphosphate) into RNA [5]. Despite 
therapy, cancer recurrence is common within the first few 
years following treatment completion, indicating stem 
cells repopulation [6] and drug resistance [7].
Base excision repair (BER) and mismatch repair 
(MMR) both play a key role in dictating cellular responses 
to 5-FU treatment, since BER recognizes and removes 
uracil and 5-FU from DNA [8] and MMR drives 5-FU-
induced cytotoxicity [9]. Greater survival benefit after 
5-FU treatment is observed in patients whose tumours are 
MMR-proficient while MMR-deficiency, characterising 
15-20% of sporadic CRC cases, is not associated with 
survival benefit after 5-FU treatment [10]. In the case of 
BER, published evidence suggests an association between 
inappropriate BER and increased tumour aggressiveness 
in CRC [for review see 11]. However, how exactly BER 
affects tumour malignancy remains to be determined since 
conflicting results are often reported on the expression of 
a limited number of BER genes [12, 13, 14]. Despite these 
limitations, BER modulation is under active investigation 
as a potential therapeutic approach for chemotherapy 
sensitization [for review see 15].
BER is a multi-step repair pathway acting on 
damaged bases generated by alkylation, oxidation or 
deamination and proceeds through a sequence of reactions 
depending on the initial base lesion [11]. BER is initiated 
upon base removal by one of many substrate-specific DNA 
glycosylases, such as N-methylpurine-DNA glycosylase 
(MPG) and 8-oxoguanine-DNA glycosylase (OGG1) [11]. 
The enzymatic steps taking place once BER is initiated 
lead to the generation of toxic intermediates such as 
apurinic/apyrimidinic (AP) sites and single strand breaks 
(SSB). Efficient BER completion is coordinated by an 
important BER accessory factor, the chromatin associated 
enzyme poly(ADP-ribose) polymerase or PARP. PARP 
is activated upon binding to sites of SSB and recruits 
downstream BER enzymes for completion of the repair 
process [16].
BER modulation may affect cellular outcomes to 
chemotherapy depending on the step in the pathway that 
is modulated. For example, preventing BER initiation by 
loss of DNA glycosylase activity may, in some instances, 
protect against the detrimental consequences of cytotoxic 
BER intermediate accumulation [for review see 17]. 
Conversely, BER imbalance by overexpression of an 
initiating glycosylase such as MPG sensitizes cancer cells 
to chemotherapeutic alkylating drugs [18]. In addition, 
once BER is initiated, PARP status can also affect cellular 
responses to chemotherapy [17]. Indeed, PARP inhibitors 
have emerged as a potential therapeutic strategy to 
increase sensitivity to chemotherapy by alkylating agents 
[19]. However, because PARP activation at SSB can also 
lead to cytotoxicity via glycolysis inhibition and energy 
depletion [20, 21, 22], disrupting energy metabolism 
through chemotherapy and BER modulation coupled to 
the remarkable dependence of cancer cells on aerobic 
glycolysis for energy production [23, 24] can represent a 
powerful approach in cancer treatment [25].
In this study, we profiled BER and MMR gene 
expression in sporadic colorectal tumours and matched 
non-tumour tissues, and related the expression of 
these DNA repair genes with clinical tumour features 
and pathological staging. We find that high BER gene 
expression is associated with poor clinical outcomes. In 
addition, we overexpressed the BER proteins MPG and 
XRCC1 in MMR-defective HCT116 cells and assessed 
how increased levels of these proteins affected cell 
survival and metabolic intermediates after 5-FU and TMZ 
treatments. We find that MPG overexpression, but not 
XRCC1 overexpression, results in increased 5-FU and 
TMZ sensitivity, ATP depletion and lactate accumulation. 
Our results suggest that BER modulation can alter both 
tumour metabolism and response to DNA damage, making 
it an attractive therapeutic target for colorectal cancer.
RESULTS
BER imbalance and reduction in MGMT 
expression characterize colorectal cancer tissues
The clinicopathological characteristics of the 70 
patients are shown in Table 1. The mRNA levels for 
MGMT (direct repair); MLH1 and MSH2 (MMR); and 
OGG1, MPG, APE1, PARP1, Polβ and XRCC1 (BER) 
were first quantified using qPCR in 70 pairs of primary 
sporadic colorectal tumours and adjacent healthy mucosal 
tissues. Gene expression data for the whole patient cohort 
is shown in Figure 1A. In addition, a diagram showing the 
relative expression of four BER genes in paired samples 
of colorectal tumours and adjacent non-tumour samples 
from 25 patients with high expression for both MPG and 
XRCC1 genes is shown in Supplementary Figure 1.
MGMT mRNA levels were reduced in tumour 
samples in comparison to healthy mucosal tissues 
(Figure 1A), and this reduction was seen in 73% of 
patients (Figure 1B). MGMT promoter methylation and 
consequently decreased expression is observed in 27-40% 
of chemo resistant metastatic colorectal tumours and is a 
frequent event in colorectal carcinogenesis [26]. However, 
since MGMT loss has been also identified in healthy 
colorectal tissue, this event has been referred as a “field 
defect”, which means it is neither necessary nor sufficient 
to cancer progression [27].
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Table 1: Clinicopathological features of CRC patients included in this study (n=70)
Variable n (%)
Total cases 70
Age (mean± SD) 67.7± 11
Age, y
 ≤65 30 (43)
 >65 40 (57)
Gender
 Male 38 (54)
 Female 32 (26)
Tumour location
 Colon 42 (60)
 Rectum 28 (40)
Histology
 Adenocarcinoma 60 (85)
 Mucinous 10 (15)
Cellular differentiation
 Well or moderately differentiated 30 (43)
 Poorly differentiated 40 (57)
Tumour invasive depth
 T1-T2 20 (29)
 T3-T4 50 (71)
Lymph node status
 N0 (n=0) 19 (27)
 N1 (n≤3) 26 (37)
 N2 (n>3) 15 (21)
Lymphatic invasion
 No 38 (54)
 Yes 32 (46)
Perineural invasion
 No 44 (63)
 Yes 26 (37)
Preoperative CEA, ng/mL
 ≤5 42 (60)
 >5 28 (40)
AJCC/TNM stage
 I-II 41 (59)
 III 29 (41)
The numbers in parentheses indicate the percentage of cases with a specific clinical or pathological characteristic.
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Differently from direct repair, BER is multi-step 
repair process that requires coordinated expression of 
several proteins to prevent accumulation of cytotoxic 
repair intermediates. With the exception of Polβ, where 
we observed no significant differences in gene expression 
levels between tumour and healthy tissues, all other 
BER genes examined were found to be overexpressed 
in tumour colorectal tissues if compared to healthy 
tissue (Figure 1A). However, it is important to note that 
a consistent upregulation for the entire group of BER 
genes was only observed in approximately 7% of our 
patient cohort (5 out of 70 patients). This means that a 
majority of sporadic CRC cases present an imbalance 
in this pathway, with some BER genes overexpressed 
without compensatory changes in downstream BER steps 
(Figure 1B).
Regarding MMR, we found no significant 
difference in expression levels for MLH1 and MSH2 
between tumour and control tissues (Figure 1A). This 
was intriguing since MLH1 inactivation was reported to 
occur in 15-20% of colorectal tumours [28]. With this in 
mind, we then analysed expression data for individual 
patients, and observed that 31% of all patients showed 
a reduction in MLH1 expression in tumour tissue in 
comparison to healthy tissue (log
2
fold change < -1) 
and 24% of patients displayed reduced expression of 
both MMR genes in neoplastic tissue (Figure 1B). It 
is well established that a functioning MMR pathway 
is necessary for the triggering of apoptosis in response 
to mispairing 5-FU induced base damage [29], and 
in the absence of MMR, the repair of such damage 
will require the BER pathway. Additionally, MMR 
deficiency is associated with better prognosis for 
colorectal cancer patients [30] but if this is associated 
to a particular BER status is currently not known. For 
this reason, we assessed a potential association between 
BER gene expression profiles and MMR status (Figure 
2). Sample classification was based on expression 
levels for both MLH1 and MSH2: samples with lower 
expression in tumour vs normal tissue for both genes 
were considered as MMR deficient, all other samples 
were designated MMR proficient (including patients 
with higher or similar expression in tumour vs. normal 
tissue). This analysis showed that deficiency in MMR 
(characterized by low MLH1 and MSH2 gene expression 
simultaneously) correlates with lower expression of 
MPG, OGG1 and PARP1, but not other BER proteins. 
While the biological relevance of this correlation is 
unclear, it raises the interesting possibility that this 
particular profile would help explain the better prognosis 
seen in MMR deficient colorectal cancer patients [30].
Next, we assessed protein expression levels by 
immunohistochemistry for MLH1, MPG, FEN1, Polβ 
and XRCC1 in tumour vs. healthy tissue of this patient 
cohort (Figure 1C and Supplementary Figure 2). Higher 
protein expression levels in tumour tissue were identified 
for MLH1, MPG, Polβ and XRCC1, respectively, in 79%, 
59%, 56% and 57% of all cases (Supplementary Table 
1). Of note, gene expression data positively correlates 
with protein expression for MLH1: r=0.699, p<0.001; 
MPG: r=0.7126, p<0.0001; Polb: r=0.3838, p=0.016 and 
XRCC1: r= 0.6641, p<0.0001.
In addition, because BER imbalance may modulate 
cell survival in a replication-dependent manner [31], 
we assessed whether overexpression of BER proteins, 
notably MPG, was associated with higher tumour 
proliferation by examining proliferating cell nuclear 
antigen (PCNA) expression in our samples. PCNA 
was overexpressed in 51 patients (69%) and it was 
positively correlated with MPG (r=0.2640, p=0.027) 
and Polβ (r=0.2833, p=0.017), but no correlation was 
found between PCNA and XRCC1 (r=-0.064, p=0.8388) 
(Supplementary Figure 3).
Changes in BER gene and protein expression 
have prognostic value in patients with colorectal 
cancer
Using regression-correlation analysis (Table 2), 
we next assessed whether the gene expression levels 
for the above proteins acting in the three distinct DNA 
repair pathways (namely, direct repair, MMR and 
BER) were associated with clinical and pathological 
features currently used for staging and prognosis 
determination in colorectal cancer patients (Figure 
3A and 3B). We find that, primary tumours located in 
rectum are associated with higher expression for both 
MLH1 (p=0.014) and MSH2 (p=0.015). Our analysis 
also showed that more aggressive mucinous histological 
subtypes are associated with higher levels of MGMT 
(p=0.027) and MPG (p=0.031) expression. Poorly 
differentiated tumours were associated with increased 
MPG (p=0.033) and XRCC1 (p=0.042) expression. 
Presence of lymphatic and/or perineural invasion is 
associated with overexpression of MPG (p=0.044 for 
lymphatic invasion), PARP1 (p=0.016 and 0.043, for 
lymphatic and perineural invasion, respectively), but 
also with reduction of Polβ gene expression (p=0.024 
and 0.003, for lymphatic and perineural invasion, 
respectively). Association between TNM stage III-
IV and high APE1 expression (p=0.018) and low 
Polβ expression (p=0.001) was also found. Finally, 
we found correlation between perioperative CEA 
(carcinoembryonic antigen) <5ng/ml and reduction of 
MSH2 gene expression (p=0.033).
We also verified the associations between clinical 
and pathological characteristics and protein expression 
(Supplementary Table 1). Overexpression of MLH1 
is associated with tumour location (p=0.002) and 
tumour invasive depth (p=0.045); high expression of 
MPG is associated with tumour location (p=0.014), 
lymphatic invasion (p=0.006) and TNM stage (p=0.008); 
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Figure 1: Sporadic colorectal tumours present imbalance of BER genes in comparison to healthy adjacent mucosa. 
A. Gene expression was quantified for a panel of DNA repair genes by real-time qPCR analysis in neoplastic and normal mucosal tissues 
from 70 patients with sporadic colorectal cancer. The following genes were examined: MGMT, MLH1, MSH2, MPG, OGG1, APE1, 
PARP1, Polβ and XRCC1. Gene expression data are shown as scatter diagrams. B. Heat map of individual gene expression changes in 
sporadic colorectal cancer. Fold changes were calculated for neoplastic tissue vs. adjacent normal tissue. Blue indicates decreased relative 
gene expression, red indicates increased relative gene expression and white indicates no change in gene expression. C. Representative 
photomicrographs showing immunohistochemical staining in colorectal tumour specimens for MLH1, MPG, Fen1, Polβ and XRCC1; N: 
normal tissue; T: tumour tissue. Images were taken at x200 magnification.
Oncotarget6www.impactjournals.com/oncotarget
overexpression of Polβ is associated with perineural 
invasion (p=0.043) and advanced TNM staging (p=0.008); 
XRCC1 overexpression is associated with histology 
(p=0.044) and presence of lymphatic invasion (p=0.005); 
while FEN1 protein expression did not present any 
significant association with clinical data.
Figure 2: MMR status (low or high gene expression of MLH1 and MSH2 simultaneously) correlation with MLH1, 
MGMT, Fen1, Polβ and XRCC1 fold change (tumour/normal tissue). Statistically significant differences (p<0.05) are 
highlighted in bold font.
Table 2: Correlations between gene expression and known clinical and pathological parameters were determined
MGMT MLH1 MSH2 MPG OGG1 APE1 PARP1 Polβ XRCC1
Age 0.518 0.147 0.585 0.441 0.226 0.888 0.377 0.522 0.819
Tumour location 0.369 0.014 0.015 0.276 0.601 0.502 0.915 0.298 0.745
Histology 0.027 0.666 0.678 0.031 0.816 0.862 0.495 0.201 0.042
Cellular 
differentiation 0.176 0.233 0.949 0.033 0.042 0.302 0.444 0.321 0.031
Tumour invasive 
depth 0.812 0.020 0.743 0.832 0.302 0.704 0.709 0.733 0.317
Lymph node status 0.125 0.848 0.537 0.164 0.983 0.188 0.439 0.003 0.345
Lymphatic invasion 0.884 0.766 0.687 0.044 0.889 0.847 0.016 0.024 0.451
Perineural invasion 0.555 0.062 0.852 0.459 0.395 0.406 0.043 0.003 0.389
Preoperative CEA 0.472 0.103 0.033 0.253 0.704 0.392 0.652 0.247 0.892
TNM stage 0.198 0.732 0.953 0.131 0.920 0.018 0.329 0.001 0.576
Associations of DNA repair gene expression with clinical parameters were evaluated using multiple linear regression 
analysis. Statistically significant gene expression correlates of clinical and pathological features are highlighted (p<0.05).
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Figure 3: Expression changes in direct repair, MMR and BER genes are associated with specific clinical and pathological 
outcomes in CRC patients. A. Correlations between gene expression and known clinical and pathological parameters were determined; 
statistical significance was assessed by correlating MMR status and BER and direct repair gene expression. Statistically significant gene 
expression correlates of clinical and pathological features are highlighted. B. Box plots showing fold change in gene expression between 
tumour tissue and normal adjacent mucosa (y axis). Horizontal lines represent the median; the bottom and top of the boxes represent the 
25th and 75th percentiles, respectively; and the vertical bars represent the range of data.
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Overexpression of MPG, but not XRCC1, 
sensitises colon cancer cells to 5-FU and 
temozolomide
Since we found that colorectal tumours that present 
increased MPG and XRCC1 mRNA and protein levels 
are more prone to unfavourable pathological outcomes, 
we decided to investigate in vitro the potential impact of 
modulating the levels of these two key BER components 
on cellular viability after exposure to 5-FU and TMZ. 
Human cells overexpressing MPG are more sensitive to 
alkylation-induced damage in a Polβ-dependent manner 
[19], but no evidence was yet reported for MPG and Polβ 
levels affecting the cellular response to 5-FU. While 
5-FU is a classic first line chemotherapeutic drug in CRC 
treatment not known to induce MPG substrates, TMZ is 
an alkylating agent inducing MPG substrates (reviewed 
in 17]., presently under investigation for metastatic CRC 
patients heavily pre-treated but non-responders (Clinical 
Trials identifiers: NCT01051596, NCT02414009).
We treated colorectal tumour HCT116 cells 
transiently overexpressing MPG or XRCC1 (Figure 4A, 
4B and 4C) with 5-FU (2.5μM and 5μM) (Figure 4D and 
4E) and with TMZ (10μM and 20μM) for 24h and 48h 
(Figure 4F and 4G). Expression levels of these exogenous 
proteins were monitored by western blotting and shown 
to be similar in the different replicate experiments (Figure 
4B). The above-mentioned doses correspond to the IC
20
 
and IC
50
, respectively, for each drug (Supplementary 
Figure 4). The MPG overexpressing colon cancer cells 
were more sensitive to both 5-FU doses after 24h and 48h 
in comparison to XRCC1-overexpressed cells (p<0.001). 
XRCC1 overexpression did not significantly affect cell 
viability to 5-FU, while MPG overexpression led to 
a significant reduction in cellular viability after 5-FU 
treatment (p<0.01), with viability reduced to 31% or 
21% 24h or 48h after treatment, respectively. The same 
scenario was observed after the TMZ IC
50
 treatment: the 
overexpression of MPG, but not of XRCC1, promoted an 
increase in cellular sensitivity to TMZ in both time points, 
and viability was reduced to 28% or 15% 24h or 48h after 
treatment, respectively (p<0.01 for both time points).
MPG overexpression increases cytosolic ATP 
levels and TMZ treatment leads to ATP depletion 
in colon cancer cells
In order to understand the mechanisms underlying 
the increased sensitivity to cytotoxic drugs that MPG - but 
not XRCC1 - overexpression promotes in colon cancer 
cells, we considered the possibility that imbalancing 
BER by MPG overexpression could induce metabolic 
dysfunction, such as ATP loss and lactate accumulation. 
Surprisingly, MPG-overexpressing cells presented a 
2-fold increase in cytosolic ATP basal levels (48h after 
the transfection) in comparison to control (p<0.001) and 
to the XRCC1-overexpressed cells (p<0.01), but no basal 
changes in lactate secretion (Supplementary Figure 5).
We then treated cells with 5-FU and TMZ and 
assessed these parameters one and four hours post-
treatment (Figure 5). ATP levels were significantly 
reduced 1 h after 5-FU treatment (2.5μM) in MPG-
overexpressing colon cancer cells, but the basal increase 
resulting from MPG overexpression meant 5-FU-treated 
cells still maintained higher ATP levels than control. 
However, after 4h, ATP levels were further reduced, 
and reached control levels (Figure 5A). Similarly, TMZ 
treatment led to even greater changes in ATP levels in 
MPG-overexpressing cells (Figure 5C). While ATP levels 
increased 1h after treatment, ATP levels dramatically 
dropped 4h after treatment, becoming even lower than 
controls. In counterpart, we did not observe any changes 
in ATP levels following 5-FU and TMZ treatments in cells 
overexpressing XRCC1 (Figure 5B and 5D).
While 5-FU treatment did not affect lactate secretion 
levels in either genotype (Figure 5F and 5G), lactate levels 
were altered by TMZ treatment. We observed a substantial 
time and dose-dependent increase in lactate accumulation 
in cells overexpressing MPG (Figure 5G) and a modest 
one in the XRCC1-overexpressed cells after 4h (Figure 
5H).
DISCUSSION
We investigated if alterations in BER, MMR and 
direct repair pathways are associated with a particular 
clinical outcome in CRC and therefore have prognostic 
value. Here, we report that BER genes are upregulated 
in a majority of sporadic CRC, represented by increases 
in MPG, OGG1, APE1, PARP1 and XRCC1 expression. 
We also report the association between these individual 
repair gene expression levels and poor outcome features 
in colorectal tumours. However, when we analysed the 
entire BER pathway as a whole for each individual CRC 
case, we noticed that there was no consistent levels of co-
expression for the BER proteins, indicating an imbalance 
or deregulation in this repair mechanism.
The classical relevance of DNA repair in sporadic 
CRC is attributed to MMR inactivation, by MLH1 and 
MSH2 loss or silencing [30], which occurs in 15-20% 
of the patients. While this characteristic is considered 
to promote better overall survival rate and modulate the 
response to 5-FU [32], individual patients with advanced 
tumour staging still present poor overall response 
rates (20–30%) [2]. Presently, however, DNA repair in 
CRC emerges as a promising strategy for personalized 
treatment. 5-FU-induced DNA damage is repaired by 
both MMR and BER, and it has been suggested that a 
crosstalk between these DNA repair pathways modulates 
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Figure 4: Overexpression of MPG, but not of XRCC1, sensitizes colon cancer cells to 5-FU and TMZ. A. representative 
photomicrographs of viable HCT116 cells displaying normal cellular morphology and exhibiting green GFP fluorescence 48h after 
transfection. B. Western blot analysis of MPG and XRCC1 protein levels in HCT116 cells 48 hours after transfection. GFP-MPG protein: 
64kD; β-Actin: 42kD; MPG: 37kD; GFP-XRCC1: 112kD; XRCC1: 85kD; Lamin-B1: 66kD. C. GFP fluorescence intensity 48h after 
transfection with the different GFP expressing vector constructs. D and E. Viability assessment of cells overexpressing GFP alone, GFP-
MPG fusion protein and GFP-XRCC1 fusion protein 24h (D) and 48h (E) after treatment with 5-FU. F and G. Viability assessment of 
cells overexpressing GFP alone, GFP-MPG fusion protein and GFP-XRCC1 fusion protein 24h (F) and 48h (G) after treatment with TMZ. 
Symbols above the error bars represent statistically significant difference (p<0.05) between cells overexpressing GFP alone and cells 
overexpressing the GFP-fusion proteins.
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Figure 5: ATP levels are modulated by MPG overexpression and 5-FU and TMZ treatments. A and B. Cytosolic ATP levels 
in MPG and XRCC1- overexpressing cells treated with 5-FU; C and D. Cytosolic ATP levels in MPG and XRCC1- overexpressed cells 
treated with TMZ; E and F. lactate secretion levels in MPG and XRCC1- overexpressed cells treated with 5-FU; G and H. lactate secretion 
levels in MPG and XRCC1- overexpressed cells treated with 5-TMZ. Symbols above the error bars represent statistically significant 
differences (p<0.01) in comparison to the cells transfected with the same plasmid that did not receive treatment. (#) Represents statistically 
significant differences (p<0.01) comparing two time points after treatment. NT: non-treated cells. Comparisons between two data sets 
(empty plasmid vs. plasmid for overexpression) are indicated individually (*p<0.01).
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cytotoxicity and resistance [32]. Thus, a potential approach 
to enhance the DNA-based mechanisms of 5-FU-mediated 
cell death is to identify how BER alterations can contribute 
to cytotoxicity.
While coordinated BER pathway avoids excessive 
toxic repair intermediate formation, such as AP sites and 
SSBs, and contributes to tumour resistance and lethal 
outcomes for the patient [11], imbalances in different 
steps of this pathway (e.g., caused by overexpression, loss 
or inhibition) are responsible for a wide range of cellular 
fates. We found that overexpression of BER genes was 
associated with clinical features that indicate tumour 
aggressiveness, such as poor cellular differentiation, 
presence of lymphatic and perineural invasion and 
advanced tumour stage. However, our analysis revealed 
that the BER pathway is likely to be imbalanced in our 
patient cohort (we define BER imbalance as tumour 
where at least three of six BER genes are altered) and we 
propose BER imbalance contributes to increased tumour 
aggressiveness in these patients. In support of this idea, 
modulation of individual BER enzymes levels was shown 
to influence several phenotypes both in vivo and in vitro. 
For example, DNA glycosylase inhibition jeopardizes 
BER initiation and results in accumulation of cytotoxic 
and mutagenic base lesions [33]; on the other hand, while 
overexpression of Polβ increases spontaneous mutagenesis 
in mammalian cells [34], Polβ downregulation leads to 
hypersensitivity to alkylation-induced DNA damage [35]. 
Yet, XRCC1-deficient mammalian cells do not properly 
repair SSBs due to inefficient DNA termini clean up and 
nick ligation [36].
The expression status of a full panel of BER genes 
had not been previously evaluated in CRC patients, and 
it is presently unclear to what magnitude MMR and 
BER collectively contribute to 5-FU and TMZ cellular 
sensitivity. Using colon cancer HCT116 cells, which 
are MMR-deficient (hMLH1-/- and hMSH3-/-), wild type 
for TP53 and MGMT-proficient [37]. we were able to 
show that MPG overexpression results in increased 
sensitization to 5-FU in colon cancer cells, despite 5-FU 
not being a known MPG substrate. MPG overexpression 
was previously reported in some types of neoplasias, 
including CRC [38, 39], however, to our knowledge, 
MPG-dependent sensitization to 5-FU in colon cancer 
cells has not been previously reported. On the other 
hand, previous reports showed that disrupting BER by 
XRCC1 depletion did not sensitize cells to 5-FU [40]. 
That XRCC1 modulation does not affect response to 
5-FU is striking given its prominent role in later steps 
of BER. One possible explanation might be altered sub-
pathway choice; long-patch BER may complete repair 
downstream of APE1-mediated incision in an XRCC1-
independent fashion. Further investigation is warranted 
to assess whether 5-FU-induced damage is repaired by 
long–patch BER, bypassing the requirement for short-
patch BER.
Interestingly, we find that MPG, but not XRCC1, 
overexpression resulted in greater sensitivity to TMZ in 
colon cancer cells. MPG overexpression was previously 
associated with cellular sensitisation to alkylation: studies 
involving breast, glioma, and ovarian cancer cell lines 
reported that MPG overexpression conferred sensitivity to 
alkylating agents, such as TMZ [19, 38]. MPG expression 
was also previously shown to predict temozolomide 
sensitivity in glioblastoma and ovarian cancer cell lines 
[16], but TMZ sensitivity in CRC was not previously 
addressed. Clinical trials for TMZ in CRC were designed 
to exploit the association between MGMT deficiency and 
increased sensitivity to temozolomide [41] [42]. Indeed, 
MGMT promoter hypermethylation and low MGMT 
expression appear to be early events in CRC patients 
[43], consistently with our clinical results. In addition, 
concomitant downregulation of both MGMT and MPG 
correlate with an improved response to TMZ [44]. Thus, 
if higher MPG levels lead to BER imbalance and a better 
response to TMZ, we suggest TMZ treatment would 
potentially benefit CRC patients and BER imbalance could 
be used as a new potential biomarker for this emerging 
CRC therapy.
MPG overexpression sensitized cells to 5-FU 
and TMZ, leading to increased ATP depletion and 
lactate accumulation upon treatment with these agents. 
However, while 5-FU treatment reduced basal ATP 
levels to control levels’ but had no effect in lactate 
accumulation, TMZ treatment led to a dramatic 
reduction in ATP levels associated with significant 
increase in lactate secretion, a scenario compatible 
to lactic acidosis. A similar metabolic dysfunction 
was already reported in several pathophysiological 
conditions, such as ischemia and diabetes [45, 46]. 
Indeed, in a streptozotocin-induced diabetes model, 
pancreatic beta-cell death was mediated by Parp-
1 activation [47] and by Mpg-initiated BER [48], 
molecular events known to contribute to tissue damage 
by depleting cells of free energy [20]. In addition, 
lactate accumulation within tumour tissue is chiefly 
due to the increased glycolytic rate of cancer cells, and 
it also correlates with metastasis and poor disease-free 
and overall survival [49]. Moreover, cell death can 
also be mediated by repression of glycolytic genes as 
a cellular response to lactate accumulation, which is 
associated with significantly increased patient survival 
rates [50]. Collectively, these results suggest that TMZ-
induced ATP depletion and high lactate may indeed 
represent a viable option to modulate patient outcomes 
to therapy.
Our data suggest that BER imbalance characterises 
sporadic CRC and influences tumour aggressiveness and 
Oncotarget12www.impactjournals.com/oncotarget
potentially patient outcome. We propose that it would be 
clinically important to assess MPG expression levels in 
sporadic colorectal cancer cases. MPG overexpression 
could increase 5-FU therapeutic efficacy so the 
identification of MPG overexpressing tumours could 
indicate a better response to therapy in these cancer 
patients.
We propose a model to depict how imbalances 
in early (such as MPG) or late (such as XRCC1) BER 
steps can alter therapeutic outcomes in CRC (Figure 6). 
Our model proposes that the metabolic characteristics of 
tumour cells contribute to tumour aggressiveness but can 
also be exploited to improve chemotherapeutic response. 
BER imbalance in initial steps (such as through MPG 
overexpression) leads to increased sensitivity to 5-FU and 
TMZ treatments and energy metabolism disruption. On the 
other hand, imbalancing BER at later steps (e.g. XRCC1 
overexpression) would not significantly alter tumour 
response to 5-FU or TMZ, since no energy metabolism 
disruption was observed in XRCC1 overexpressing cells 
upon 5-FU or TMZ treatment.
In light of our results, we propose TMZ is an 
attractive candidate for a new chemotherapy approach in 
CRC. Our findings in HCT116 cells, which are MGMT 
proficient and MMR deficient, support the idea that TMZ-
induced N-methylpurines rather than O6-methylguanine 
adducts significantly contribute to cell death in MMR-
deficient cells. TMZ may be especially effective in 
MMR-deficient MPG-overexpressing colon cancer cells, 
concomitantly inducing DNA damage and disrupting 
metabolism, potentially leading to higher therapeutic 
efficiency for this subset of CRC patients.
Figure 6: Model depicting the potential therapeutic value of BER status assessment in colorectal cancer. BER pathway 
imbalance can be therapeutically exploited to benefit MMR-deficient colorectal cancer patients. MMR-deficient sporadic CRC patients 
derive little benefit from chemotherapy, Modulation of early BER steps (i.e. MPG overexpression) results in enhanced sensitivity to DNA 
damage and energy metabolism disruption, representing therefore an attractive therapeutic target for this subset of CRC patients.
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MATERIALS AND METHODS
Patients
A total of 70 surgically resected fresh tissue 
specimens comprising of tumour tissues (percentage of 
tumour cells >70%) and adjacent normal tumour-free 
regions (non tumour healthy mucosa at >10 cm distance 
from the tumour) of primary sporadic CRC were collected 
between 2013 and 2015. Only cases with a primary 
diagnosis of colorectal cancer undergoing upfront surgery 
were selected for the purpose of this study. We excluded 
patients who had received pre-operative treatment in the 
form of radiation or chemotherapy. We also excluded 
patients with family history of Familiar Adenomatous 
Polyposis (FAP) and Hereditary Non-polyposis Colorectal 
Cancer (HNPCC). Histopathological grades and clinical 
staging were evaluated according to the standard criteria 
described in the sixth edition of AJCC/UICC Classification 
by pathologists blinded for the study purposes. Ethical 
committees of participating institutions approved the 
study, and written informed consent was obtained from 
patients before study enrolment. The study was carried 
out in accordance with the principles of the Helsinki 
Declaration.
Quantitative reverse transcription PCR
We evaluated the differential gene expression in 
colorectal tumours and healthy paired tissues in duplicate 
by RT2 Profiler™ PCR Array (SABiosciences/Qiagen). 
The selected genes composing the arrays were: MPG, 
OGG1, APEX1, PARP1, Polβ and XRCC1 from the BER 
pathway; MLH1 and MSH2 from the MMR pathway; and 
the direct repair gene MGMT.
Regions of high tumour cellularity (minimum 
of 80%) were selected for RNA extraction. RNA 
was extracted and purified from 30 mg of both fresh 
tumours and adjacent mucosa samples using an RNeasy 
mini kit (SABiosciences/Qiagen) according to the 
manufacturer’s instructions. cDNA was synthesized from 
1 µg of total RNA using the RT2 PCR Array First Strand 
Kit (SABiosciences/Qiagen) according to supplier’s 
recommendations. Reaction was prepared using RT2 
SYBR-Green/Rox PCR Master Mix (SABiosciences/
Qiagen). Data analysis was based on the ΔΔCT method 
with normalization of the raw data to two housekeeping 
genes (EIF2B and PPIA).
Immunohistochemistry
MLH1, MPG, FEN1, POLβ and XRCC1 expression 
in primary tumours was examined from formalin-fixed 
paraffin-embedded samples. Tissues were sectioned 
at 4-μm and mounted on silanized slides, which were 
stored at 4oC. After deparaffinization and rehydration, 
the sections were quenched with 3% H
2
O
2
 in methanol 
to block endogenous peroxidase. Bovine serum albumin 
at 5% (BSA) was then applied to prevent non-specific 
binding. The sections were incubated with anti-MPG 
(dilution 1:100, Abcam, mouse, EPR10959(B)), anti-Polβ 
(dilution 1:500, Abcam, rabbit, ab26343), anti-FEN1 
(dilution 1:800, Abcam, rabbit, ab17993), anti-XRCC1 
(dilution 1:50, Abcam, mouse, ab1838), anti-MLH1 
(dilution 1:100, Abcam, ab92312) and PCNA (dilution: 
1:400, mouse, #2586) antibodies, and then incubated 
with appropriate secondary antibodies (DAKO). 
Diaminobenzidine (DAB) was used as chromogen and 
the sections were counterstained with haematoxylin. 
Omission of the primary antibody was used as a negative 
control. Protein expression was evaluated using Quick 
Score (QS) (by assessing both staining intensity and the 
percentage of the stained area with a given intensity) and 
dichotomized in low (score between 0 and 4) and high 
expression (score between 5 and 12) (Supplementary 
Material and Methods). Only stained nuclei of malignant 
cells were assessed.
Cell culture and transfection
The human colorectal cancer cell line HCT116 
was obtained from the American Type Culture Collection 
and cultured in McCoy’s 5A Medium (Gibco) containing 
10% FBS (Sigma), penicillin (107 U/L) and streptomycin 
(10 mg/L), maintained at 37°C in a humidified 5% CO
2
 
incubator. The HCT116 cell line was authenticated 
at the DNA Diagnostics Center (DDC) from Public 
Health England (PHE) using short tandem repeat (STR) 
methodology and used within 5 months of thawing a 
frozen vial. The plasmid allowing for the overexpression 
of a GFP-MPG fusion protein was a kind gift from Clara 
F. Charlier in the Meira lab, while the GFP-XRCC1 
fusion construct was a kind gift from Dr Akira Yasui. 
For transient transfections, cells were seeded into 96-
well plates at 1x104 cells per well. After 24 hours, cells 
were transfected with Lipofectamine 2000 following the 
manufacturer’s protocol (Invitrogen). After 5 hours of 
incubation at 37°C, the transfection medium was replaced 
with fresh complete medium. All experiments were 
performed in triplicate and 48h after transfection. Basal 
values correspond to the 48h post-transfection time point 
but without intervention.
Cytotoxic drugs treatment
5-FU and TMZ were purchased from Sigma-Aldrich 
and reconstituted in DMSO, aliquoted and maintained at 
-20oC. 48h after transfection, chemotherapeutic agents 
at the desired concentrations were added into each well 
and plates were incubated for 24h and 48h (for viability 
assays) or for 1h and 4h (for metabolic measurements) in 
an incubator with 5% CO
2
 at 37°C.
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Cell viability assay
Viability was assessed with the CellTiter-Aqueous 
MTS reagent (Promega), 24 and 48 h post-treatment. 
Briefly, MTS reagent was added into each well and 
incubated for 3h with 5% CO
2
 at 37°C. MTS absorbance 
was then measured at 490nm. Results are reported as the 
percentage of treated cells relative to the cells without 
treatment (% Control).
Western blot
Cell lysates were obtained with mammalian cell 
lysis buffer M-PER (PIERCE) containing protease 
inhibitors (Sigma). Protein content was determined with 
the BCA Protein Assay according to manufacturer’s 
instructions (Pierce, Thermo Fisher Scientific). Twenty 
micrograms of protein lysate was loaded onto a SDS-
PAGE gel (Bio-Rad) and transferred eletrophoretically 
onto a polyvinylidene fluoride membrane. The membranes 
were blocked overnight with PBS containing 0.1% Tween 
20 in 5% skim milk at 4°C and subsequently probed 
using the following primary antibodies: anti-MPG (1:250, 
Sigma, HPA006531), anti-XRCC1 (1:500, Abcam, 
ab1838), anti-β-Actin (1:2000, Abcam, mouse ab6276 
and rabbit ab52614) and anti-Lamin-B1 (1:2000, mouse 
ab8983 and rabbit ab133741). Detection followed by 
incubation with IRDye® 800CW Goat anti-Rabbit IgG or 
IRDye 680RD Goat anti-Mouse IgG (both from LI-COR). 
Membranes were scanned using an Odyssey CLx infrared 
imaging system (LI-COR Biosciences).
ATP and lactate measurements
For lactate measurements, medium was sampled 
from cells 1h and 4h after treatment and deproteinized 
with Amicon centrifugal filters (Merck Millipore) for 
lactate dehydrogenase removal. Colorimetric method 
was performed with lactate assay kit (Sigma-Aldrich) 
following the manufacturer’s instructions. Absorbance 
was read at 570 nm.
For ATP measurements, cells were lysed with 
digitonin-based buffer (Cayman). Intracellular ATP was 
determined by a luciferin/luciferase method using an ATP 
bioluminescent assay kit (Sigma-Aldrich). Luminescence 
was measured using a 96-well plate luminometer. 
Cytosolic ATP content was calculated by an ATP standard 
curve and normalized to cellular protein content/well.
Statistical Analysis
Clinical data was analysed using SPSS version 22.0 
(SPSS Inc.). Qualitative variables were compared using the 
χ2 Test and Fisher’s exact test; and quantitative variables 
were analysed by the t test. Univariate analysis of clinical 
factors including age, sex, TNM stage, tumour invasion, 
lymph node metastases, cellular differentiation, location and 
tumour size was assessed by the log-rank test. Experimental 
data was analysed with GraphPad Prism 6 software 
(GraphPad) and statistical analysis carried out by two-way 
ANOVA and Tukey’s post-hoc. The results were considered 
statistically significant when p-value was less than 0.05.
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